Transfusion Medicine Reviews
Volume 23, Issue 2 , Pages 124-133 , April 2009

Properties of Pathogen-Inactivated Plasma Components

  • Christopher Prowse

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Christopher Prowse, MA, DPhil, FRCPathol, Research Director, National Science laboratory, SNBTS, 21 Ellen's Glen Road, EH17 7 QT, Edinburgh, United Kingdom.

References 

  1. Webert KE, Cserti CM, Hannon J, et al. Proceedings of a Consensus Conference: Pathogen inactivation-making decisions about new technologies. Transfus Med Rev. 2008;22:1–34
  2. Horowitz B, Bonomo R, Prince AM, et al. Solvent/detergent-treated plasma: A virus-inactivated substitute for fresh frozen plasma. Blood. 1992;79:826–831
  3. Biesert L, Suhartono H. Solvent/detergent treatment of human plasma—A very robust method for virus inactivation. Validated virus safety of OCTAPLAS. Vox Sang. 1998;74(Suppl 1):207–212
  4. Lambrecht B, Mohr H, Knüver-Hopf J, Schmitt H. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang. 1991;60:207–213
  5. Lin L, Hanson CV, Alter HJ, et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion. 2005;45:580–590
  6. Goodrich RP. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang. 2000;78(Suppl 2):211–215
  7. Ruane PH, Edrich R, Gampp D, et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion. 2004;44:877–885
  8. Burnouf-Radosevich M, Burnouf T, Huart JJ. A pasteurized therapeutic plasma. Infusionsther Transfusionsmed. 1992;19:91–94
  9. Burnouf T, Radosevich M, El-Ekiaby M, et al. Nanofiltration of single plasma donations: Feasibility study. Vox Sang. 2003;84:111–119
  10. O'Shaugnessy DF, Atterbury C, Bolton-Maggs P, et al. for the British Committee for Standards in Haematology. Guidelines for the use of fresh frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126:11–28with December 2005 update: http://www.bcshguidelines.com/pdf/Amendments_FFP_091205.pdf
  11. Stanworth SJ, Brunskill SJ, Hyde CJ, et al. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol. 2004;126:139–152
  12. Garwood M, Cardigan R, Drummond O, et al. The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma. Transfusion. 2003;43:1238–1247
  13. Osselaer JC, Debry C, Goffaux M, et al. Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: Methylene blue and amotosalen. Transfusion. 2008;48:108–117
  14. Schlenke P, Hervig T, Isola H, et al. Photochemical treatment of plasma with amotosalen and UVA light: Process validation in three European blood centers. Transfusion. 2008;48:697–705
  15. Cardigan R, Prowse C, Williamson LM. Processing and components: Leucoreduction and pathogen reduction. In:  Barbara JAJ,  Regan FAM,  Contreras MC editor. Transfusion Microbiology. Cambridge University Press; 2008;p. 239–258
  16. Zeiler T, Wittmann G, Zimmermann R, et al. The effect of virus inactivation on coagulation factors in therapeutic plasma. Br J Haematol. 2000;111:986–987
  17. Doyle S, O'Brien P, Murphy K, et al. Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma. Blood Coagul Fibrinolysis. 2003;14:283–287
  18. Yarranton H, Lawrie AS, Purdy G, et al. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med. 2004;14:39–44
  19. Hornsey VS, Drummond O, Morrison A, et al. Pathogen reduction of fresh plasma using riboflavin and UV light: Effects on plasma coagulation proteins. Transfusion. 2008;(submitted for publication)
  20. Coignard BP, Colquhoun SD, Nguyen GT, et al. Intra-operative deaths in liver transplant recipients associated with the use of solvent/detergent plasma. Hepatology. 2002;36:A209;(abstract)
  21. Salge-Bartels U, Breitner-Ruddock S, Hunfeld A, et al. Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe. Transfusion Medicine. 2006;16:266–275
  22. Magner JJ, Crowley KJ, Boylan JF. Fatal fibrinolysis during orthotopic liver transplantation in patients receiving solvent/detergent-treated plasma (Octaplas). J Cardiothorac Vasc Anesth. 2007;21:410–413
  23. de la Rubia J, Arriaga F, Linares D, et al. Role of methylene blue–treated fresh frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol. 2001;114:721–723
  24. Alvarez-Larren A, Del Rio J, Ramirez C, et al. Methylene blue–photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang. 2004;86:246–251
  25. Cardigan R, Allford S, Williamson LM. Levels of von Willebrand factor cleaving protease are normal in methylene blue treated fresh frozen plasma. Br J Haematol. 2002;117:253–254
  26. Koenigbauer UF, Eastlund T, Day JW. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent treated pooled plasma. Transfusion. 2001;41:1203–1206
  27. Ciaravino V, McCullough T, Cimino G. The role of toxicology assessment in transfusion medicine. Transfusion. 2003;43:1481–1492
  28. Pohler P, Leuschner F, Gravemann U, et al. In: Methylene blue–treated plasma: Toxicological profile of methylene blue and its photoproducts. Poster presented at the 37th Congress of the DGTI, Mannheim, September 21-24. 2004;(abstract)
  29. Borgman MA, Spinella PC, Perkins JG, et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma. 2007;63:805–813
  30. Hellstern P, Larbig E, Walz GA, et al. Prospective study on efficacy and tolerability of solvent/detergent-treated plasma in intensive care unit patients. Infusionsther Transfusionsmed. 1993;20(suppl 2):16–18
  31. Inbal A, Epstein O, Blickstein D, et al. Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders. Blood Coagul Fibrinolysis. 1993;4:599–604
  32. Solheim BG, Svennevig JL, Mohr B, et al. The use of Octaplas in patients undergoing open heart surgery. In:  Muller-Berghaus G editors. DIC: Pathogenesis, Diagnosis and Therapy of Disseminated Intravascular Fibrin Formation. Amsterdam: Elsevier; 1993;p. 253–262
  33. Horowitz MS, Pehta JC. SD plasma in TTP and coagulation factor deficiencies for which no concentrates are available. Vox Sang. 1998;74(suppl 1):231–235
  34. Pehta JC. Clinical studies with solvent detergent-treated products. Transfus Med Rev. 1996;10:303–311
  35. Williamson LM, Llewelyn CA, Fisher NC, et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion. 1999;39:1227–1234
  36. Wieding JU, Rathgeber J, Zenker D, et al. Prospective randomized and controlled study on solvent/detergent versus methylene blue/light virus-inactivated plasma. Transfusion. 1999;39(suppl):23s;(abstract)
  37. Beck KH, Mortelsmans Y, Kretschmer VV, et al. Comparison of solvent/detergent-inactivated plasma and fresh frozen plasma under routine clinical conditions. Infusionsther Transfusionsmed. 2000;27:144–148
  38. Lerner RG, Nelson J, Sorcia E, et al. Evaluation of solvent/detergent-treated plasma in patients with a prolonged prothrombin time. Vox Sang. 2000;79:161–167
  39. Haubelt H, Blome M, Kiessling AH, et al. Effects of solvent/detergent-treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang. 2002;82:9–14
  40. Solheim BG, Bergan A, Brosstad F, et al. Fibrinolysis during liver transplant and use of solvent/detergent virus-inactivated plasma (ESDEP/Octaplas). Anesth Analg. 2003;96:1230–1231author reply 1231-1232 (letter)
  41. Solheim BG. Universal pathogen-reduced plasma in elective open-heart surgery and liver resection. Clin Med Res. 2006;4:209–217
  42. Tollofsrud S, Noddeland H, Svennevig JL, et al. Universal fresh frozen plasma (Uniplas): A safe product in open-heart surgery. Intensive Care Med. 2003;29:1736–1743
  43. Solheim BG, Granov DA, Juravlev VA, et al. Universal fresh-frozen plasma (Uniplas): An exploratory study in adult patients undergoing elective liver resection. Vox Sang. 2005;89:19–26
  44. Chekrizova V, Murphy WG. Solvent-detergent plasma: Use in neonatal patients, in adult and paediatric patients with liver disease and in obstetric and gynaecological emergencies. Transfus Med. 2006;16:85–91
  45. McCarthy LJ. The experience of treating patients with thrombotic thrombocytopenic purpura with solvent detergent plasma. Br J Haematol. 2006;133:107;author reply 108 (letter)
  46. Flamholz R, Jeon HR, Baron JM, Baron BW. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: Is its decreased protein S activity clinically related to their development of deep venous thromboses. J Clin Apheresis. 2000;15:169–172
  47. Yarranton H, Cohen H, Pavord SR, et al. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol. 2003;121:778–785
  48. Wieding JU, Neumeyer H. Initial experiences with methylene blue virus inactivated fresh frozen plasma: Results of a clinical and in vitro study. Infusionsther Transfusionsmed. 1992;19:84–90
  49. Pohl U, Mohr H. Virus inactivation of plasma by methylene blue/light exposure: Clinical experience. Transfus Today. 1994;2:2–3
  50. Pohl U, Beyer HJ. Safety and tolerance of methylene blue virus inactivated fresh frozen plasma: The lower saxony experience. In: ISBT Regional Conference (Venice). 1995;(abstract)
  51. Pohl U, Wieding JU. Treatment of patients with severe congenital coagulation factor V or XI deficiency with methylene blue virus inactivated plasma. In: ISBT Vth Regional (European) congress, Venice. 1995;(abstract)
  52. Pohl U, Becker M. Methylene blue virus inactivated fresh frozen plasma in the treatment of patients with thrombotic thrombocytopenic purpura. In: ISBT Vth Regional (European) congress, Venice. 1995;(abstract)
  53. Pohl U, Mohr H. Experiences in the Clinical Use of Plasma Photodynamically Virus Inactivated by the Methylene Blue/Light Procedure 24th Congress of the ISBT 1996: Poster 1/2E-41 OP (abstract)
  54. Hernandez JM, Castella D, Claparols M, et al. Clinical use of fresh frozen plasma virus inactivated with methylene blue. Transfusion. 1999;39:25S;(S94P) (abstract)
  55. Simonsen AC, Sorensen H. Clinical tolerance of methylene blue virus-inactivated plasma: A randomized crossover trial in 12 healthy human volunteers. Vox Sang. 1999;77:210–217
  56. Atance R, Pereira A, Ramírez B. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion. 2001;41:1548–1552
  57. Mintz PD, Neff A, MacKenzie M, Goodnough LT, et al. A randomized, controlled phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion. 2006;46:1693–1704
  58. Hambleton J, Wages D, Radu-Radulescu L, et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion. 2002;42:1302–1307
  59. Hambleton J, Wages D, Radu-Radulescu L, et al. In: The Kinetics of Proteins C & S Activity are Retained in Intercept Plasma (IFFP) poster at Paris IST Congress July. 2001;(abstract)
  60. de Alarcon P, Benjamin R, Dugdale M, et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: Transfusion of patients with congenital coagulation factor deficiencies. Transfusion. 2005;45:1362–1372
  61. Mintz PD, Bass NM, Petz LD, et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood. 2006;107:3753–3759
  62. Flesland O. A comparison of complication rates based on published haemovigilance data. Intensive Care Med. 2007;33(Suppl 1):S17–S21
  63. Renaudier P, Schlanger S, Mai MPV, et al. on behalf of the French Hemovigilance Network Epidemiology of transfusion related acute lung injury in France: Preliminary results. Transfus Med Hemother. 2009;35:89–91
  64. AuBuchon JP, Birkmeyer JD. Safety and cost-effectiveness of solvent-detergent–treated plasma. In search of a zero-risk blood supply. JAMA. 1994;272:1210–1214
  65. Jackson BR, AuBuchon JP, Birkmeyer JD. Update of cost-effectiveness analysis for solvent-detergent treated plasma. J Am Med Assoc. 1999;282:329–330
  66. Pereira A. Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion. 1999;39:479–487
  67. Riedler GF, Haycox AR, Duggan AK, Dakin HA. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang. 2003;85:88–95

PII: S0887-7963(08)00108-9

doi: 10.1016/j.tmrv.2008.12.004

Transfusion Medicine Reviews
Volume 23, Issue 2 , Pages 124-133 , April 2009

Article Tools